DDInter826 DDInter1592
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifapentine
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Glipizide {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Glipizide {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifapentine (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) resembles Rifapentine (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Glipizide (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)
Glipizide (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)